short stories

2 Houston organizations announce strategic appointments across finance and research

Here are two of the latest updates on new appointments from two Houston organizations. Photos courtesy

Two Houston innovators have new roles they're excited about this summer. From new academia to bitcoin, here's who's moving and shaking in Houston innovation.

Rice University names vice president for research

Ramamoorthy Ramesh joins Rice to lead research. Photo via Rice.edu

Rice University named Ramamoorthy Ramesh, a condensed matter physicist and materials scientist with more than 25 years of experience, as vice president for research. He most recently chaired energy technology and taught physics at the University of California, Berkeley. He is expected to start his new position on August 15. He follows Yousif Shamoo, who served as in the position for eight years, and Doug Natelson, has acted as interim since June.

“Ramesh comes to Rice with a distinguished research career and a wealth of experience and knowledge in various types of research enterprises,” says newly inducted Rice President Reginald DesRoches. “I am confident he will be a transformational leader who can strengthen Rice’s reputation as a center of increasingly impactful and broad-based interdisciplinary research that retains a deep commitment to pedagogy and the student experience.”

In addition to his extensive leadership at Berkeley, Ramesh was the founding director of the U.S. Department of Energy SunShot Initiative, deputy director of science and technology at Oak Ridge National Laboratory, and associate laboratory director at the Lawrence Berkeley National Laboratory, per a news Rice release.

“Building upon its rapidly rising research portfolio, Rice has the potential to further strengthen and expand its engagement with public and private funding agencies and be the science and technology beacon for the world,” he says in the release. “I look forward to helping make that happen and to engaging on behalf of the university at various state, national and international fora of relevance to the Rice research enterprise.”

Bitcoin expert joins Houston financial firm

Lisa Hough has a new title. Image courtesy of LevelField

Houston-based LevelField Financial has named Lisa Hough as the company’s head of business development. The financial services firm focuses on uniting digital assets and traditional banking services onto one platform. Hough, with her background in bitcoin and energy trading, will focus on expanding LevelField's market presence and report to Gene A. Grant, II, founder and CEO of the company.

“Lisa is the perfect addition to LevelField's veteran banking and financial service executive team. Her experience will meet our clients’ wants and needs, which are well-managed and regulated investment products that blend established and emerging digital assets,” says Grant in a news release. "Lisa's ability to connect with clients will enable them to rapidly build a well-informed perspective on digital assets.”

Hough has a decade of experience in natural gas trading and risk management at energy trading organizations, including Vastar Resources, Enron, and PG&E National Energy Group, and is a frequent speaker at global finance and energy conferences.

“My passion is to educate and connect all people to bitcoin because it is the only form of property that can be held by every human on earth, regardless of property rights,” she says in the release.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted